09/09/2022
08/09/2022
29/07/2022
12/02/2021
EuropaBio sees the Directive on cross-border healthcare as an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases.
20/01/2021
Read our submission to the European Commission’s Inception Impact Assessment titled “Revision of the EU legislation on medicines for children and rare diseases“.
30/11/2020
Call for more effective EU regulation of clinical trials with Advanced Therapy
Medicinal Products consisting of or containing Genetically Modified Organisms
20/10/2020
EuropaBio Position Paper on the use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making.
19/10/2020
EuropaBio and its members would like to engage the European Commission and all relevant stakeholders in a discussion on the future use of the HE in the context of the new EU Pharmaceutical Strategy and its accompanying actions.
30/09/2020
EuropaBio Patient engagement with the European Medicines Agency
13/08/2020
Read our Statement in response to the publication of the European Commission’s evaluation of the Orphan and Paediatric Regulations.
03/08/2020
Health industry sectors, representing pharmaceutical and medical technology companies welcome the publication of the Partnership Proposal as a significant milestone towards a European Partnership for Health Innovation.
30/07/2020
Joint response of EuropaBio and BIO on the EU Data Strategy Consultation.
30/07/2020
EuropaBio response to the public consultation on the Roadmap for an EU Pharmaceutical Strategy.
30/07/2020
Read our response on the eHSG Work Programme 2020-2022.
15/07/2020
Read our position paper on the Farm to Fork strategy.
30/06/2020
EuropaBio welcomes the European Commission’s commitment to develop a European plan to fight cancer and is supportive of its overarching approach in tackling all key stages of the disease: prevention, early diagnosis, treatment, and quality of life. Above all, we strongly advocate the employment of supportive measures for health innovation to ensure that novel cancer treatments move from the laboratory to the hospital bedside as swiftly as possible.
22/06/2020
Read our position on the EU 2030 Biodiversity Strategy.